CyBio AG Adds Thomas Moore as a member of the Company's Executive Management Board
Advertisement
The Supervisory Board of CyBio AG appointed Thomas Moore as a member of the Company's Executive Management Board responsible for Sales and R&D effective September 1, 2009. The appointment of the 53 year old Thomas Moore, who has worked for the Company since its foundation in 1996, is meant to bundle and to further strengthen the responsibilities in these areas. CyBio will not be effected with additional costs due to the expansion of the management.
Thomas Moore, who has directed the Company OPALJENA, that has been traded as CyBio Instruments since 1999, as Executive Manager until 2002. From 1991 to 1996 he managed the R&D activities of JENOPTRON. Moore possesses broad experience in the fields of optics, optoelectronics, lab automation and liquid handling. Recently he managed the new life science department at CyBio AG, that will prospectively contribute to the Company`s sales increase.
Most read news
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Large international study finds memory in adults impacted by versions of 4 genes - Second study identifies brain-development genes associated with intracranial volume
Evolva acquires resveratrol programme from Fluxome
Network that plays crucial role in cell function and disease
Celera Genomics Receives NIH Grant to Develop and Commercialize Avian Flu Diagnostic Test